EUVIMEDEUVIMED entdecken
Crossref

Genome Editing: Moving Toward a New Era of Innovation, Development, and Approval

Houria Bachtarzi iD

Human Gene Therapy · 2023

DOI: 10.1089/hum.2022.230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2023. Verfasst von Houria Bachtarzi. Beteiligte Einrichtung: Precision for Medicine (UK), Ltd. London, United Kingdom. Hauptthemen laut MEDLINE: Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic genome editing is currently reshaping and transforming the development of advanced therapies as more ex vivo and in vivo gene editing-based technologies are used to treat a broad range of debilitating and complex disorders. With first-generation gene editing modalities (notably those based on ZFNs, TALENs and CRISPR/Cas9), comes a new second-generation of gene editing-based therapeutics including base editing, prime editing and other nuclease-free genome editing modalities. Such ground-breaking innovative products warrant careful considerations from a product development and regulatory perspective, that take into account not only the common development considerations that apply to standard gene and cell therapy products, but also other specific considerations linked with the technology being used. This article sheds light into specific considerations for developing safe and effective in vivo and ex vivo genome editing medicines that will continue to push barriers even further for the cell and gene therapy field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingGenetic TherapyEndonucleasesTranscription Activator-Like Effector NucleasesZinc Finger NucleasesCRISPR-Cas Systems

Stichwörter der Autor:innen

approvalclinical studiesoff-target gene editingproduct developmentsensitivityunbiased genome-wide analysis

Substanzen

EndonucleasesTranscription Activator-Like Effector NucleasesZinc Finger Nucleases

Autor:innen und Institutionen

  • Precision for Medicine (UK), Ltd. London, United Kingdom.

ORCID-Profile: Houria Bachtarzi

Zitieren

APA

Bachtarzi, H. (2023). Genome Editing: Moving Toward a New Era of Innovation, Development, and Approval. Human Gene Therapy. https://doi.org/10.1089/hum.2022.230

Vancouver

Bachtarzi H. Genome Editing: Moving Toward a New Era of Innovation, Development, and Approval. Human Gene Therapy. 2023. doi:10.1089/hum.2022.230

BibTeX
@article{Bachtarzi2023,
  author = {Bachtarzi, Houria},
  title = {Genome Editing: Moving Toward a New Era of Innovation, Development, and Approval},
  journal = {Human Gene Therapy},
  year = {2023},
  doi = {10.1089/hum.2022.230}
}
Kostenlos starten →